history of glp-1 agonists Historical timeline biology, receptor agonist discovery, and Trends in the Development of

Fahima Azizi & Dr

This study investigates the effects of allulose, a rare sugar shown to reduce blood glucose, in a rat model of diet-induced obesity and T2D

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

Quality Assurance & Verification

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

Blue Cross and Blue Care Network came to this decision after careful consideration of GLP-1 weight loss drugs efficacy, safety and access and skyrocketing costs.